These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8080631)

  • 1. Complications of corticosteroid therapy.
    Talar-Williams C; Sneller MC
    Eur Arch Otorhinolaryngol; 1994; 251(3):131-6. PubMed ID: 8080631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of the adverse reactions to adrenal corticosteroids.
    Frauman AG
    Adverse Drug React Toxicol Rev; 1996 Nov; 15(4):203-6. PubMed ID: 9113247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacology of glucocorticoids].
    Le Jeunne C
    Presse Med; 2012 Apr; 41(4):370-7. PubMed ID: 22341947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the role of glucocorticoids in inflammation.
    Ronchetti S; Migliorati G; Bruscoli S; Riccardi C
    Clin Sci (Lond); 2018 Jul; 132(14):1529-1543. PubMed ID: 30065045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of autoimmune blistering diseases.
    Rico MJ
    Cutis; 1993 Dec; 52(6):357-61. PubMed ID: 8293677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Corticosteroid sensitivity, dependence and resistance in inflammatory and immunologic diseases. Physiopathologic review].
    Franchimont D; Belaiche J; Geenen V
    Rev Med Liege; 1998 Jan; 53(1):33-7. PubMed ID: 9555181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammation, glucocorticoids and risk of cardiovascular disease.
    Buttgereit F; Burmester GR; Lipworth BJ
    Nat Clin Pract Rheumatol; 2009 Jan; 5(1):18-9. PubMed ID: 19048007
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacology of glucocorticoids and ENT pathology].
    Devillier P
    Presse Med; 2001 Dec 22-29; 30(39-40 Pt 2):59-69. PubMed ID: 11819915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Side-effects of anti-inflammatory therapy in uveitis.
    Uchiyama E; Papaliodis GN; Lobo AM; Sobrin L
    Semin Ophthalmol; 2014; 29(5-6):456-67. PubMed ID: 25325874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic use of glucocorticoids and immunosuppressive agents].
    Grbović L; Radenković M
    Srp Arh Celok Lek; 2005 Oct; 133 Suppl 1():67-73. PubMed ID: 16405260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of autoimmune premature ovarian failure.
    Kalantaridou SN; Braddock DT; Patronas NJ; Nelson LM
    Hum Reprod; 1999 Jul; 14(7):1777-82. PubMed ID: 10402388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoids.
    Spies CM; Strehl C; van der Goes MC; Bijlsma JW; Buttgereit F
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):891-900. PubMed ID: 22265268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid.
    Miserocchi E; Baltatzis S; Roque MR; Ahmed AR; Foster CS
    Ophthalmology; 2002 Jan; 109(1):111-8. PubMed ID: 11772589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhalational and topical steroids, and oral candidosis: a mini review.
    Ellepola AN; Samaranayake LP
    Oral Dis; 2001 Jul; 7(4):211-6. PubMed ID: 11575870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions.
    Watad A; Amital H; Shoenfeld Y
    Lupus; 2017 Sep; 26(10):1015-1022. PubMed ID: 28420062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive techniques to limit glucocorticoid-induced side effects.
    Vittorio CC; Werth VP
    Adv Dermatol; 2000; 16():273-97; discussion 298. PubMed ID: 11094631
    [No Abstract]   [Full Text] [Related]  

  • 17. [Benefits and risks of treatments used in systemic autoimmune diseases].
    Mouthon L
    Rev Med Interne; 2008 Jun; 29 Spec No 2():15-23. PubMed ID: 18927989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacologic constraints imposed by the blood-brain barrier: the example of multiple sclerosis].
    Jolliet P
    Rev Neurol (Paris); 2000 Jul; 156(6-7):681-3. PubMed ID: 10891808
    [No Abstract]   [Full Text] [Related]  

  • 19. [New glucocorticoids are more selective. Current knowledge can eliminate serious adverse effects].
    Nilsson S; Gustafsson JA
    Lakartidningen; 1997 Jun; 94(26-27):2465-71. PubMed ID: 9235445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [112th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: How to Use Glucocorticoids in Systemic Autoimmune Diseases].
    Kawai S
    Nihon Naika Gakkai Zasshi; 2015 Sep; 104(9):1937-43. PubMed ID: 30160903
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.